- Novartis scraps mid-stage radiopharma asset as Pluvicto soarsThe discontinued asset, being trialed for breast cancer and solid tumors, had yielded disappointing data, leading to Novartis’ decision to abandon development, according to a company spokesperson.BioSpace · 5d ago↗ source
- Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics spa…BioSpace · 5d ago↗ source
- STAT+: ‘Cochlear implant for blindness’ debuts in Europe, could launch in U.S. in 2027Science Corporation announced the European launch of its retinal implant for patients with age-related macular degeneration.